MA
VRTX icon

MCF Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

MCF Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88K Sell
197
-57
-22% -$26.6K ﹤0.01% 516
2025
Q4 		$115K Buy
254
+71
+39% +$30.6K 0.01% 383
2025
Q3 		$71.7K Buy
183
+16
+10% +$6.69K ﹤0.01% 369
2025
Q2 		$74.3K Hold
167
– – ﹤0.01% 353
2025
Q1 		$81K Sell
167
-7
-4% -$3.26K 0.01% 338
2024
Q4 		$70.1K Hold
174
– – ﹤0.01% 355
2024
Q3 		$80.9K Sell
174
-2
-1% -$961 0.01% 329
2024
Q2 		$82.5K Buy
176
+18
+11% +$7.81K 0.01% 322
2024
Q1 		$66K Sell
158
-5
-3% -$2.11K 0.01% 338
2023
Q4 		$66.3K Buy
163
+7
+4% +$2.59K 0.01% 339
2023
Q3 		$54.2K Buy
156
+110
+239% +$38.5K ﹤0.01% 345
2023
Q2 		$16.2K Hold
46
– – ﹤0.01% 503
2023
Q1 		$14.5K Buy
46
+39
+557% +$11.7K ﹤0.01% 521
2022
Q4 		$2.02K Hold
7
– – ﹤0.01% 677
2022
Q3 		$2K Hold
7
– – ﹤0.01% 698
2022
Q2 		$2K Hold
7
– – ﹤0.01% 648
2022
Q1 		$2K Buy
+7
New +$1.66K ﹤0.01% 662
2021
Q4 		– Sell
-12
Closed -$2K – 668
2021
Q3 		$2K Buy
+12
New +$2.34K ﹤0.01% 640

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MCF Advisors's VRTX Position: Q1 2026 in Review

MCF Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q1 2026, selling an estimated $26.6K and leaving 197 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #516.

MCF Advisors first reported a position in VRTX in Q3 2021 and has held it in 18 quarters since. The position peaked at $115K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • MCF Advisors held 197 shares of Vertex Pharmaceuticals worth $88K as of Q1 2026.
  • MCF Advisors sold 57 Vertex Pharmaceuticals shares in Q1 2026, an estimated $26.6K.
  • Vertex Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #516 holding.
  • MCF Advisors first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • MCF Advisors's Vertex Pharmaceuticals position peaked at $115K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.